Biopharmaceutical company Incyte Corporation (NASDAQ: INCY) will be reporting results this Tuesday before the bell. Here’s what to look for.

Incyte beat analysts’ revenue expectations last quarter, reporting revenues of $1.51 billion, up 27.8% year on year. It was a satisfactory quarter for the company, with an impressive beat of analysts’ revenue estimates but a significant miss of analysts’ EPS estimates.

Is Incyte a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, the market is expecting Incyte’s revenue to grow 15.4% year on year, slowing from the 19.5% increase it recorded in the same quarter last year.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Incyte rarely misses Wall Street’s revenue estimates.

With Incyte being the first among its peers to report earnings this season, we don’t have anywhere else to look to get a hint at how this quarter will unravel for biotechnology stocks. However, there has been positive investor sentiment in the segment, with share prices up 10.1% on average over the last month. Incyte is up 3.9% during the same time .

ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.

Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.